15
Sep
2022

Third Harmonic Revives IPO Market, PDUFA Deadline Nears, & Pfizer Aims mRNA at Flu

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Eisai and Biogen Bounce Back, Amylyx Approved, & Illumina’s Big Reveal
GSK Lifts Up Spero, AlphaFold Inventors Honored, and a Microbiome Milestone
Amylyx’s ALS Surprise, Regeneron’s Eye Franchise Win & Roche Buys Good
FDA Clears Bivalent Vaccines, Novo Buys Forma, & Novartis R&D Chief Moves On